Developed by IMMG · Manufacturing in Kazakhstan
IMMG is developing TromboCheck and preparing to manufacture it in Kazakhstan. TromboCheck is the first solution in the HomeLab product series: an accessible POCT solution for patients and healthcare organisations.
TromboCheck · HomeLab
TromboCheck is designed as a simple, clear and accessible POCT solution. The 3D prototype already defines its appearance: a large display, physical buttons and a compact housing that sits comfortably in the hand.
Haemostasis
Haemostasis is the body’s system that helps stop bleeding and prevent unnecessary blood clots. This balance can be disturbed in either direction.
Excessive clotting
Haemostasis
Balance
Insufficient clotting
1 in 4
According to World Thrombosis Day, an initiative founded by the International Society on Thrombosis and Haemostasis (ISTH), 1 in 4 people worldwide die from conditions related to thrombosis.
19.8 million
According to WHO estimates, cardiovascular diseases caused 19.8 million deaths in 2022 — around 32% of all deaths worldwide.
85% of cardiovascular deaths were due to heart attack and stroke.
Source: World Health Organization — Cardiovascular diseases (CVDs)
1 in 4
According to WHO, 1 in 4 adults is predicted to experience a stroke in their lifetime.
Ischaemic stroke is caused by blocked blood flow; haemorrhagic stroke is caused by bleeding.
≈25%
According to the CDC, sudden death is the first symptom in about a quarter of people with pulmonary embolism.
CDC statistics refer to data from the United States.
> 1/3
More than a third of VTE cases diagnosed each year are related to a recent hospitalisation. The CDC describes VTE as a leading cause of preventable hospital death in the United States.
The other side of haemostasis. Clotting disorders can involve not only excessive clot formation but also a reduced ability of the blood to clot, which increases the risk of prolonged or heavy bleeding.
Source: National Heart, Lung, and Blood Institute — Bleeding Disorders
These figures describe the scale of the medical problem, not the capabilities of a specific device. TromboCheck’s functions, indications and specifications will be published only after they are confirmed by documentation.
This section explains why the field matters. It is not a claim that TromboCheck can diagnose or prevent the conditions listed.
The scale of haemostasis disorders highlights the importance of accessible, clear tools that can be used closer to the patient. This is the field in which IMMG is creating TromboCheck — the first solution in the HomeLab series.
These materials are provided for information purposes and do not replace advice from a medical professional.
The role of a POCT solution
Many tests still depend on laboratory infrastructure. An accessible POCT solution could bring some of them closer — to the patient and to the place where medical decisions are made. This is the format in which TromboCheck is being created.
A clear solution — without medical jargon or unnecessary complexity.
A practical tool designed for use at the point of care.
Specific indications for use, the list of tests and specifications will be published only after they are confirmed by documentation.
TromboCheck roadmap
TromboCheck is following a step-by-step path from a technology prototype to a finished medical device. The project is currently at the production preparation stage.
Project status update — 30.10.2026
Defining the product’s purpose, operating principle and TromboCheck’s place within the HomeLab series.
Creating the 3D prototype together with technology partner Alwex: working out the device’s display, controls and housing.
Status update
Moving from prototype to production: the device configuration is being refined, and the technical documentation and organisation of production in Kazakhstan are being prepared.
Target period to be confirmed
Target period to be confirmed
Target period to be confirmed
Target period to be confirmed
Manufacturing in Kazakhstan. A project goal, not an achieved result
TromboCheck is approaching production. IMMG is steadily preparing the device, its documentation and the production site in Kazakhstan.
The roadmap reflects the current development plan and may be refined as technical and regulatory stages are completed.
IMMGHomeLabTromboCheck
HomeLab by IMMG
HomeLab is IMMG’s lead long-term product series. Its aim is to develop clear and accessible medical solutions that can be used closer to the patient. TromboCheck opens the series; further solutions will be introduced within it.
IMMG — the developer
IMMG — International Medical Management Group — is a medical company based in Kazakhstan. We are developing the HomeLab product series and preparing production of its first solution, TromboCheck. Our experience with laboratories helps us understand the real needs of healthcare infrastructure.
Mission
We work to make essential medical solutions more accessible and closer to people.
Make medical solutions more accessible to organisations and people.
Develop the preventive side of healthcare.
Strive to help reduce mortality and support the long-term development of healthcare.
Bring health monitoring closer to the patient and the point of care.
Manufacturing in Kazakhstan
IMMG is preparing to manufacture TromboCheck at a site in the Akmola Region. Preparation is under way: the device configuration is being finalised, and the technical documentation and organisation of the production process are being prepared.
The set of documents needed to move from prototype to production.
Finalising the housing, kit contents and software.
Necessary testing, regulatory preparation and a future pilot batch.
TromboCheck production site — preparing to start production
16 Valentin Kuzmin Street, Nauchny settlement, Shortandy District, Akmola Region, Republic of KazakhstanThe interactive map is loaded from Yandex Maps only after you click the button.
Partnerships and distribution
Supplying instruments and reagents to laboratories is an additional line of work that runs alongside our own development. IMMG is an official distributor of EMKO Group and KazTestLine LLP.
Official distributor
IMMG is an official distributor of EMKO Group.
Official distributor
IMMG is an official distributor of KazTestLine LLP.
Technology partner
IMMG’s technology partner in creating the TromboCheck 3D prototype.
We supply laboratories and healthcare organisations with the instruments, reagents and solutions that laboratory infrastructure needs.
Cooperation
We are open to professional dialogue — from the use of HomeLab solutions to manufacturing and investment partnerships.
Information about TromboCheck, future use scenarios, instruments and reagents.
Get in touchComponents, manufacturing, engineering and technology development of the device.
Get in touchDiscussing future formats for distributing HomeLab solutions.
Get in touchThe company’s mission, manufacturing in Kazakhstan and the potential of the HomeLab series.
Get in touchContacts
Email or call directly — you will reach the Director of IMMG.
Office: Astana, 8 Mangilik El Avenue, premises 18
ContactsContact person
Akylzhan Zankoyev
Director, IMMG
Please mention your organisation and the subject of your question. The website does not collect or store your data: the email is sent from your own mailbox.